Merohua again to meet the opponent of the second domestic lytoxi single anti-listing.

Pharma.com October 12, according to the official website of the State Drug Administration data, Cyntaf's Lytoxidan anti-injection (commodity people: Dabohua) was approved for listing, according to the announcement issued by Xinda Bio, the drug will be used to treat diffuse large B-cell lymphoma, follicle lymphoma and chronic lymphocytic leukemia, which is the second domestic approved listed enterprises after Fuhong Hanxuan.
public information shows that the primary drug for lysiocyte monoantigene is Merohua, the first monoclonal antibody approved by the FDA to treat cancer by Roche Genentech, since its launch in 1997 Merohua has been approved for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, hemanitis granuloma, multi-angiotis under the microscope, moderate to severe adult herpes and other adaptations.
2000, Merohua was approved to enter the Chinese market with CD20-positive fage and diffuse large B-cell type non-Hodgkin's lymphoma, initially priced at 500mg/50ml/bottle 16041 yuan, 100mg/10ml/bottle 3416 yuan, 201 7 years, to reduce the price to 8298 yuan and 2418 yuan to enter the National Health Insurance Category B directory, followed by the state tax concessions and adjustments, Merohua since the second half of 2018 in the provinces began to gradually adjust the price reduction, 100mg/10ml/bottle specifications from 2418 yuan to 2294.44 yuan.
February 22, 2019, Merohua welcomed its first domestic rival, Hanlikang of Fuhong Hanxuan, the first biosypolion drug approved in China and incorporated into Shanghai Health Insurance.
relevant data show that Hanlikang's initial 100mg/10ml/bottle/spec agreement purchase price is 1648 yuan, the personal quota self-contained standard is 650 yuan.
compared with the original drug Merott, its price is about 29% lower, last August, Hanlikang carried out the first price adjustment, its winning bid in Guizhou Province purchase price of 1398 yuan / bottle, the price compared to Merott, the price is about 39% lower.
according to Fosun Pharma's 2019 financial results, Hanlikang has achieved sales of 150 million yuan since its listing. two months after
went on sale in Hanley, Pfizer's rituximab-pvvr was approved by the U.S. FDA for the treatment of a variety of adult blood tumors and autoimmune diseases, including non-Hodgkin's lymphoma.
the launch of two biosynthic drugs has affected Merro's sales to some extent.
According to Roche's 2019 results, Mello's full-year sales last year were SFr6,477 million, down 4% from SFr6,752 million in 2018, and its revenue in the first quarter of this year was SFr1,389 million, down 15% from a year earlier, with revenues in japan, Europe and the United States all down.
In response to fierce competition in the market, it has been reported this year that from October 1 this year, Roche will cancel the melohua previous sales indicators of the assessment system, new patients into the group, meetings, visits, regional sinking and so on may become a new assessment program.
part of the development of lytoxi mono-resistance enterprises (photo source: Pharmaceutical Rubik's Cube PharmaGO database) according to the Pharmaceutical Rubik's Cube PharmaGO database shows that there are a number of domestic enterprises in the development of lytoxi single-resistance, including Hualan Biological, Sansheng Guojian, Nanjing Yuke Bio, Zhejiang Terris Pharmaceuticals, Lizhu Pharmaceuticals, Shenzhen Wanle Pharmaceuticals, Shanghai Institute of Biological Products, etc., among them, some enterprises have been developed in phase III clinical stage.
.